Methods and compositions for treating disease-related cachexia

Abstract

A method of treating disease-related cachexia comprises administering to a subject a composition comprising an anti-AGE antibody. A composition for treating disease-related cachexia comprises a first anti-AGE antibody, a second anti-AGE antibody and a pharmaceutically acceptable carrier. The first anti-AGE antibody is different from the second anti-AGE antibody. A method of treating or preventing the onset of disease-related cachexia comprises immunizing a subject in need thereof against AGE-modified proteins or peptides of a cell.

What is claimed is: 
     
         1 - 6 . (canceled) 
     
     
         7 . A method of treating or preventing the onset of disease-related cachexia, comprising immunizing a subject in need thereof against AGE-modified proteins or peptides of a cell. 
     
     
         8 - 23 . (canceled) 
     
     
         24 . The method of  claim 7 , wherein the immunizing comprises administering a vaccine comprising an AGE antigen. 
     
     
         25 . The method of  claim 24 , wherein the vaccine comprises
 (a) the AGE antigen,   (b) an adjuvant,   (c) optionally, a preservative, and   (d) optionally, an excipient.   
     
     
         26 . The method of  claim 24 , wherein the vaccine is administered in an amount effective to cause the immune system to produce antibodies to cells having AGE-modified proteins or peptides. 
     
     
         27 . The method of  claim 24 , wherein the AGE antigen is an AGE-modified protein or peptide selected from the group consisting of AGE-RNAse, AGE-human hemoglobin, AGE-human serum albumin, AGE-low density lipoprotein, AGE-collagen IV, AGE-antithrombin III, AGE-calmodulin, AGE-insulin, AGE-ceruloplasmin, AGE-collagen, AGE-cathepsin B, AGE-albumin, AGE-BSA, AGE-human serum albumin, AGE-ovalbumin, AGE-crystallin, AGE-plasminogen activator, AGE-endothelial plasma membrane protein, AGE-aldehyde reductase, AGE-transferrin, AGE-fibrin, AGE-copper/zinc SOD, AGE-apo B, AGE-fibronectin, AGE-pancreatic ribose, AGE-apo A-I and II, AGE-hemoglobin, AGE-Na + /K + -ATPase, AGE-plasminogen, AGE-myelin, AGE-lysozyme, AGE-immunoglobulin, AGE-red cell Glu transport protein, AGE-β-N-acetyl hexominase, AGE-apo E, AGE-red cell membrane protein, AGE-aldose reductase, AGE-ferritin, AGE-red cell spectrin, AGE-alcohol dehydrogenase, AGE-haptoglobin, AGE-tubulin, AGE-thyroid hormone, AGE-fibrinogen, AGE-β 2 -microglobulin, AGE-sorbitol dehydrogenase, AGE-α 1 -antitrypsin, AGE-carbonate dehydratase, AGE-RNAse, AGE-low density lipoprotein, AGE-hexokinase, AGE-apo C-I, AGE-KHL and mixtures thereof. 
     
     
         28 - 52 . (canceled) 
     
     
         53 . The method of  claim 24 , wherein the AGE antigen comprises carboxymethyllysine conjugated with keyhole limpet hemocyanin (CML-KLH).